At Biostax we strive to advance select and efficient small-scale biotechnology, pharmaceutical and MedTech programs through subsidiaries, investment vehicles and partnerships utilizing a biotech portfolio hub-and-spoke business model. Products will be deployed from these programs in targeted U.S. and international markets for initial commercialization.

Biostax is therapeutic and health tech agnostic, constantly seeking assets with low acquisition costs and high growth opportunities having significant clinical and commercial potential. The company targets small-scale early-stage entrepreneurs, inventors and universities and creates efficient hyper-focused entities designed specifically to advance the development of the drugs or technology while providing shared resources and synergies among partners.

Flexible deal-structuring practices enables rapid engagement of time-sensitive opportunities, and provides Biostax with multiple options to build the best corporate structure for the development and commercialization of each product.

Management
Board of Directors

Latest News

Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception20231130144754

Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception

Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception Orlando...
Read more

The Selection Process

Selection

A well-organized meticulous review process is in place for each opportunity prior to becoming an official asset. Before committing capital, the SRT (Subsidiary Review Team) will review several parameters to vet an early-stage opportunity with underlying science as the critical parameter for development projects and commercial viability for late-stage licensed and approved projects.

Scientific Review

The Scientific review process is handled by the Scientific Review Team comprised of employees, members of the SRT, outside consultants and strategic partners depending on the target asset. Members will review such things as mechanistic rationales and available clinical and pre-clinical data before passing the opportunity on to our operational and commercialization members.

Operational & Commercial Review

Operation and commercialization members will review several parameters including subsidiary team composition, commercial viability in the market space, overall competition, and IP position.

Milestone Review Process

In addition to asset review, assessment, and recommendation, the SRT is highly focused on creating a de-risked capital allocation environment though the following practices: Milestone Review Funding for In-development Assets, Operational and Commercial Milestone Funding for Approved Assets, Optimizing Flexible Subsidiary Ownership and Improving Portfolio Breadth and Diversification

Meet the Biostax Team

Our continued and future success is a product of the tireless work of our executive officer and our scientific, financial, regulatory and legal members and consultants

CEO; Founder

Noreen Griffin
President

Kelly Wilson
CFO

Glen Farmer, M.B.A.
VP of Strategy; Director

Robert Wilson
CEO; Founder

Noreen Griffin

Ms. Griffin has nearly 15 years’ experience in senior executive leadership and corporate development roles. She has been involved in the biotech/pharmaceutical industries for more than a decade, and was instrumental in establishing many relationships that are central to the success of Biostax. Ms. Griffin has significant expertise in developing business opportunities in emerging markets, especially in Africa.

Email:info@biostax.net

Phone:1-888-391-9355

President

Kelly Wilson

Ms. Wilson has over 10 years’ experience in biotechnology and more than twenty-five years’ experience in project management, systems design, data management, and information technology. She has held senior management and development roles with both start-ups and large corporations in the private, public, and government sectors across multiple industries including biotechnology, manufacturing, and software development. She was formerly the Company’s Chief Technology Officer and then the Chief Operating Officer before taking this position. Ms. Wilson graduated with honors from the University of Central Florida with a Master of Arts degree in Instructional Systems Design and prior to that received a Bachelor of Arts degree in English.

Email:info@biostax.net

Phone:1-888-391-9355

CFO

Glen Farmer, M.B.A.

Mr. Farmer has over 30 years of experience creating and scaling Finance, Accounting and Operations for startup and development-stage companies. He has held numerous, senior financial roles with start-up and large corporations in the private and public sectors across multiple industries. Glen previously held CFO positions with Croma Pharma N. America and Primetime Life Sciences, and served as Controller and Principal Accounting Officer for Avalon Pharmaceuticals.
Mr. Farmer received his bachelor’s degree in accounting from the University of Maryland, and his MBA with concentration in finance from Mount St. Mary’s University.

Email:info@biostax.net

Phone:1-888-391-9355

VP of Strategy; Director

Robert Wilson

Mr. Wilson has spent more than 25 years building and launching companies. As a business strategist, retail marketer and content developer, he is experienced in assessing business situations, conducting research, creating strategic plans, recommending solutions to management, monitoring competitors, and measuring the results of marketing strategies. Mr. Wilson has been involved in securing more than $150 million in early round and angel funding, developing launch and pivot strategies and identifying growth opportunities for more than two dozen public companies ranging from the energy sector and electric vehicles to healthcare and life style brands. The past 10 years of Mr. Wilson’s career were spent focused on the healthcare and life sciences industries, with dedication to the biopharmaceuticals, research & development and specialty pharmaceuticals verticals.

Email:info@biostax.net

Phone:1-888-391-9355